271 related articles for article (PubMed ID: 32845900)
1. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study.
Engeda JC; Lhachimi SK; Rosamond WD; Lund JL; Keyserling TC; Safford MM; Colantonio LD; Muntner P; Avery CL
PLoS Med; 2020 Aug; 17(8):e1003280. PubMed ID: 32845900
[TBL] [Abstract][Full Text] [Related]
2. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
[TBL] [Abstract][Full Text] [Related]
3. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year.
Tran JN; Kao TC; Caglar T; Stockl KM; Spertus JA; Lew HC; Solow BK; Chan PS
J Manag Care Spec Pharm; 2016 Aug; 22(8):901-8. PubMed ID: 27459652
[TBL] [Abstract][Full Text] [Related]
5. Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study.
Eastwood SV; Mathur R; Sattar N; Smeeth L; Bhaskaran K; Chaturvedi N
PLoS Med; 2021 Jun; 18(6):e1003672. PubMed ID: 34185782
[TBL] [Abstract][Full Text] [Related]
6. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
[TBL] [Abstract][Full Text] [Related]
7. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
8. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.
Shah RV; Spahillari A; Mwasongwe S; Carr JJ; Terry JG; Mentz RJ; Addison D; Hoffmann U; Reis J; Freedman JE; Lima JAC; Correa A; Murthy VL
JAMA Cardiol; 2017 Jun; 2(6):644-652. PubMed ID: 28315622
[TBL] [Abstract][Full Text] [Related]
9. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
Mortensen MB; Nordestgaard BG
JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
11. Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis.
Shah RV; Allison MA; Lima JA; Bluemke DA; Abbasi SA; Ouyang P; Jerosch-Herold M; Ding J; Budoff MJ; Murthy VL
Atherosclerosis; 2015 Sep; 242(1):211-7. PubMed ID: 26209814
[TBL] [Abstract][Full Text] [Related]
12. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.
Bellows BK; Olsen CJ; Voelker J; Wander C
J Manag Care Spec Pharm; 2016 Aug; 22(8):892-900. PubMed ID: 27459651
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
Jacobs JA; Addo DK; Zheutlin AR; Derington CG; Essien UR; Navar AM; Hernandez I; Lloyd-Jones DM; King JB; Rao S; Herrick JS; Bress AP; Pandey A
JAMA Cardiol; 2023 May; 8(5):443-452. PubMed ID: 36947031
[TBL] [Abstract][Full Text] [Related]
14. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.
Egan BM; Li J; White K; Fleming DO; Connell K; Hernandez GT; Jones DW; Ferdinand KC; Sinopoli A
J Am Heart Assoc; 2016 Aug; 5(8):. PubMed ID: 27543306
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
16. Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.
Mufarreh A; Shah AJ; Vaccarino V; Kulshreshtha A
JAMA Netw Open; 2023 Jan; 6(1):e2251156. PubMed ID: 36656581
[TBL] [Abstract][Full Text] [Related]
17. Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk.
Sarraju A; Spencer-Bonilla G; Chung S; Gomez S; Li J; Heidenreich P; Palaniappan L; Rodriguez F
J Gen Intern Med; 2022 Aug; 37(11):2642-2649. PubMed ID: 34505981
[TBL] [Abstract][Full Text] [Related]
18. Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease.
Spencer-Bonilla G; Chung S; Sarraju A; Heidenreich P; Palaniappan L; Rodriguez F
J Am Geriatr Soc; 2021 Apr; 69(4):979-985. PubMed ID: 33410499
[TBL] [Abstract][Full Text] [Related]
19. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
[TBL] [Abstract][Full Text] [Related]
20. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
